

Updated: Feb 2025

EDUCATION and TRAINING

Post-doctoral Research Fellow, Substance Use Epidemiology	2017 – 2020
<i>Department of Epidemiology, Columbia University Mailman School of Public Health</i>	
Doctor of Philosophy, Health Services Research and Policy	2017
<i>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health</i>	
Certificate of Bioethics and Public Health Policy	2015
Master of Health Science	2013
<i>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health</i>	
Bachelor of Arts, majors in Psychology and Spanish, minor in Biology	2007
<i>University of Virginia</i>	

ACADEMIC APPOINTMENTS

Assistant Professor of Health Systems and Policy	2020 – present
<i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	
Core Faculty, Center for Pharmacoepidemiology and Treatment Science	2022 – present
<i>Institute for Health, Health Care Policy, and Aging Research</i>	
Associate Director for Research, Center for Health Services Research	2020 – 2022
<i>Institute for Health, Health Care Policy, and Aging Research</i>	

SCHOLARLY APPOINTMENTS

Associate Member	2022 – present
<i>Rutgers Institute for Nicotine and Tobacco Studies (INTS)</i>	
Member, TL1 Program Advisor	2020 – present
<i>New Jersey Alliance for Clinical and Translational Sciences (NJ ACTS)</i>	

HONORS and AWARDS

- Society of Scholars, New Jersey Alliance for Clinical and Translational Sciences inducted 2022
- Outstanding Reviewer, Annals of Internal Medicine 2021
- Early Career Investigator Award, Addiction Health Services Research Conference 2020
- Delta Omega Honorary Society in Public Health inducted 2018
- Marilyn Bergner Award in Health Services Research 2016
- June Culley Doctoral Scholarship in Health Policy and Management 2015

GRANTS and FELLOWSHIPS

- NIH/NIDA (R01 DA058664; Role: Co-I) 2024 – 2029
Improving Outcomes and Equity for Released Prisoners with OUD: Trajectories of Participation in Pre-Release and Post-Release MOUD, Peer Navigation, and Outcomes

- NIH/NIDA (R01 DA059042; Role: Co-I) 2023 – 2028
The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid Use
- NIH/NIDA (R01 DA053243; Role: Co-I) 2022 – 2027
Role of disability and pain in opioid overdose: mechanism and risk mitigation
- NIH/NIDA (R01 DA057568; Role: Co-I) 2022 – 2027
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability
- NIH/NIDA (R21 DA062273; Role: MPI) 2024 – 2026
Informing national overdose prevention and treatment strategies for high-risk adolescents
- NIH/NIDA (K01 DA049950; Role: PI) 2020 – 2025
Multi-Level Associations Between Opioid Use and Overdose: Individual, Clinical, and Population-Based Risk Factors for Fatality
- NIH/NIDA (R01 DA047347; Role: Co-I) 2021 – 2024
Fatal and Non-Fatal Opioid Overdose Risk Following Prison Release: Associations with Individual Risk Factors, In-Prison Medications for Opioid Use Disorder, and Peer Navigation
- NIH Loan Repayment Program Award (L30 DA046889; Role: PI) 2018 – 2023
- NRSA Post-doctoral Research Fellowship (T32 DA031099; Role: Trainee) 2017 – 2020
- NRSA Pre-doctoral Research Training Fellowship (T32 HS000029; Role: Trainee) 2013 – 2016

PEER-REVIEWED PUBLICATIONS

*Asterisks denote trainees unless otherwise specified

1. Stone EM, *Bonsignore S, Crystal S, **Samples H**. Disabled patients' experiences of healthcare services in a nationally representative sample of U.S. adults. *Health Serv Res*. In press.
2. Fink D, **Samples H**, Malte CA, Olfson M, Wall M, Alschuler D, Saxon A, Hasin D. Cannabis legalization and increasing cannabis use in the United States: Data from urine toxicology testing in emergency room patients. *Int J Drug Policy*. In press.
3. Gupta S, James A, Miles J, **Samples H**, Crystal S, Simon K. Unwinding Medicaid's enrollment freeze – Trends in access to medications for opioid use disorder. *JAMA Health Forum*. In press.
4. **Samples H**, *Cruz N, Corr A, Akkas F. National Trends and Disparities in Suicidal Ideation, Attempts, and Health Care Utilization Among U.S. Adults. *Psychiatr Serv*. 2025;76(2):110-119. PMID: 39308172.
5. Martins SS, Bruzelius E, Mauro CM, Santaella-Tenorio J, Boustead AE, Wheeler-Martin K, **Samples H**, Hasin DS, Fink DS, Rudolph KE, Crystal S, Davis CS, Cerdá M. The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use? *Int J Drug Policy*. In press.
6. Doonan SM, Wheeler-Martin K, Davis C, Mauro C, Bruzelius E, Crystal S, Mannes Z, Gutkind S, Keyes KM, Rudolph K, **Samples H**, Henry SG, Hasin D, Martins S, Cerdá M. How do restrictions on opioid prescribing, harm reduction, and treatment coverage policies relate to opioid overdose deaths in the United States in 2013-2020? An application of a new state opioid policy scale. *Int J Drug Policy*. 2025;137:104713.
7. **Samples H**, Lloyd K, Ryali R, Martins SS, Cerdá M, Hasin D, Crystal S, Olfson M. Completeness and quality of managed care data compared with fee-for-service data in national Medicaid claims from 2001 to 2019. *Health Serv Res*. 2025 Jan 2;e14429
8. Bushnell GA, Horton DB, Olfson M, **Samples H**, Suarez EA, Calello DP. Current utilization of bupropion treatment in children, young adults, and adults in the United States. *J Child Adolesc*

Psychopharmacol. 2024 Dec 20. [Epub ahead of print].

9. Rudolph KE, Williams NT, Diaz I, Forrest S, Hoffman KL, **Samples H**, Olfson M, Doan L, Cerdá M, Ross R. Pain management treatments and opioid use disorder risk in Medicaid patients. *Am J Prev Med.* 2024;67(6):878-886. PMCID: PMC11585455.
10. *Cruz N, Duberstein P, **Samples H**. Racial/ethnic differences in risk of suicidal ideation and suicide attempts in a nationally representative sample of U.S. adolescents. *J Affect Disord.* 2024;365:32-35. PMID: 39142591.
11. Williams AR, Mauro CM, Chiodo L, Huber B, Cruz A, Crystal S, **Samples H**, Nowels M, Wilson A, Friedmann PD, Remien RH, Olfson M. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. *Drug Alcohol Depend.* 2024;263:112389. PMCID: PMC11384240.
12. Mannes ZL, *Nowels M, Mauro C, Cook S, Gutkind S, Bruzelius E, Wheeler-Martin K, Gutkind S, Bruzelius E, Doonan SM, Crystal S, Davis CS, **Samples H**, Hasin DS, Keyes KM, Rudolph KE, Cerdá M, Martins SS. The combined relationship of prescription drug monitoring program enactment and medical cannabis laws with chronic pain-related healthcare visits. *J Gen Int Med.* 2024 Oct 1; [Epub ahead of print].
13. Xu K, Nascimento F, Lin B, Park TW, Maust DT, ***Samples H**, *Bushnell G. Benzodiazepine Receipt in Adults with Psychogenic Non-Epileptic Seizures in the United States. *BMJ Neurol Open.* 2024;6(2):e000767. PMCID: PMC11418548.
*Co-senior authors
14. Hoffman K, Milazzo F, Williams N, **Samples H**, Olfson M, Diaz I, Doan L, Cerdá M, Crystal S, Rudolph K. Independent and joint contributions of physical disability and chronic pain to incident opioid use disorder and opioid overdose among Medicaid patients. *Psychol Med.* 2024;54(7): 1419-1430. PMCID: PMC10994776.
15. Williams AR, Mauro CM, Huber B, Chiodo L, Crystal S, **Samples H**, Olfson M. Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement. *Am J Psychiatry.* 2024;181(5): 457-459. PMCID: PMC11152114.
16. Mauro PM, Gutkind S, Askari MS, Hasin DS, **Samples H**, Mauro CM, Boustead AE, Martins SS. Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019. *Drug Alcohol Depend.* 2024;257:111113.
17. Tipping A, *Nowels M, Williams AR, **Samples H**, Olfson M, Crystal S, Woodruff J. Medications for opioid use disorder are associated with reduced risk of repeat opioid overdose in Medicaid: A cohort study. *J Subst Use Addict Treat.* 2024;157:209218. PMCID: PMC10922317.
18. *Nowels MA, Duberstein PR, Crystal S, Treitler P, Miles J, Olfson M, **Samples H**. Suicide within 1 year of non-fatal overdose: Risk factors and risk reduction with medications for opioid use disorder. *Gen Hosp Psychiatry.* 2024;86:24-32. PMCID: PMC10880030.
19. Miles J, Treitler P, Hermida R, Nyaku AN, Simon K, Gupta S, Crystal S, **Samples H**. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. *Drug Alcohol Depend.* 2023;252:110963. PMCID: PMC10615876.
20. **Samples H**, Levy NS, Bruzelius E, Segura LE, Mauro PM, Boustead AE, Mauro C, Martins SS. Association between legal access to medical cannabis and frequency of non-medical prescription opioid use among U.S. adults. *Int J Ment Health Addict.* 2023 Oct [Epub ahead of print].
21. Miles J, Treitler P, Lloyd J, **Samples H**, Mahone A, Hermida R, Gupta S, Duncan A, Baaklini V, Simon K, Crystal S. Racial and ethnic disparities in buprenorphine receipt among Medicare Beneficiaries, 2015-19. *Health Aff.* 2023;42(10):1431-1438. PMCID: PMC10910625.
22. **Samples H**, *Nowels M, Williams AR, Olfson M, Crystal S. Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. *Am J Prev Med.* 2023;65(1):19-29. PMCID: PMC10293066.

23. Williams AR, Mauro CM, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Performance measurement for opioid use disorder medication treatment and care retention. *Am J Psychiatry*. 2023;180(6):454-457. PMID: PMC10130230.
24. Treitler P, **Samples H**, Hermida R, Crystal S. Association of a state prescribing limits policy with opioid prescribing and long-term use: an interrupted time series analysis. *J Gen Int Med*. 2023;38(8):1862-1870. PMID: PMC10271990.
25. Treitler P, *Nowels M, **Samples H**, Crystal S. Buprenorphine utilization and prescribing among New Jersey Medicaid beneficiaries after adoption of initiatives designed to improve treatment access. *JAMA Netw Open*. 2023;6(5):e2312030. PMID: PMC10163388.
26. Bruzelius E, Cerdá M, Davis CS, Jent V, Wheeler-Martin K, Mauro CM, Crystal S, Keyes KM, **Samples H**, Hasin DS, Martins SS. Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states. *Int J Drug Policy*. 2023;114:103980.
27. Hamilton LK, Wheeler-Martin K, Davis CS, Martins SS, **Samples H**, Cerdá M. A modified Delphi process to identify experts' perceptions of the most beneficial and harmful laws to reduce opioid-related harm. *Int J Drug Policy*. 2022;108:103809. NIHMSID: NIHMS1840454.
28. **Samples H**, Williams AR, Crystal S, Olfson M. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. *J Subst Abuse Treat*. 2022;139:108774. PMID: PMC9187597.
29. Williams AR, Mauro C, Feng T, Wilson A, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder. *J Subst Abuse Treat*. 2022;39:108770. PMID: PMC9187606.
30. Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, **Samples H**, Gupta S. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. *JAMA Netw Open*. 2022 Jun 1;5(6):e2214765. PMID: PMC9161014.
31. Bushnell G, **Samples H**, Gerhard T, Calello DP, Olfson M. Benzodiazepine and Stimulant Prescriptions Before Overdose in Youth. *Pediatrics*. 2022;149(4):e2021055226. PMID: PMC9097826.
32. Crystal S, *Nowels M, **Samples H**, Olfson M, Williams AR, Treitler P. Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients. *Drug Alcohol Depend*. 2022;232:109269. PMID: PMC8943804.
33. Mauro P, Gutkind S, Annunziato E, **Samples H**. Utilization of medication for opioid use disorder in a representative sample of U.S. adolescents and adults with need for treatment, 2019. *JAMA Netw Open*. 2022;5(3):e223821. PMID: PMC8943638.
34. Crystal S, *Nowels M, Olfson M, **Samples H**, Williams AR, Treitler P. Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration. *J Subst Abuse Treat*. 2021;131:108456. PMID: PMC8664984.
35. Martins SS, Bruzelius E, Stingone JA, Wheeler-Martin K, Akbarnejad H, Mauro CM, Marziali M, **Samples H**, Crystal S, Davis CS, Rudolph KE, Keyes KM, Hasin DS, Cerdá M. Prescription opioid laws and opioid-dispensing in U.S. counties: Identifying salient law provisions with machine learning. *Epid*. 2021;32(6):868-876. PMID: PMC8556655.
36. Mauro P, **Samples H**, Klein K, Martins SS. Discussing drug use with health care providers is associated with perceptions and receipt of drug use treatment in the United States: We need to talk. *Med Care*. 2020;58(7):617-624. PMID: PMC8112806.
37. **Samples H**, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. *Health Aff*. 2020;39(5):747-55. PMID: PMC7531057.

38. *Williams AR, **Samples H**, Olfson M, Crystal S. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. *Am J Psychiatry*. 2020;177(2): 117-124. PMID: PMC7002204.
*Published with commentary: Connery HS, Weiss RD. Discontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know? *Am J Psychiatry*. 2020;177(2):104–106.
39. ***Samples H**, Stuart EA, Saloner B, Barry CL, Mojtabai R. The Role of Screening in Depression Diagnosis and Treatment in a Representative Sample of US Primary Care Visits. *J Gen Int Med*. 2020;35(1):12-20. PMID: PMC6957618.
*Published with commentary: Jackson JL, Machen JL. From the Editors' Desk: The Importance of Screening for Depression in Primary Care. *J Gen Intern Med*. 2020;35(1):1-2.
40. ***Samples H**, Stuart EA, Olfson M. Opioid Use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults. *Am J Epidemiol*. 2019;188(7):1245-1253. PMID: PMC6601526.
*Selected as Editor's Choice
41. **Samples H**, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. *J Subst Abuse Treat*. 2018;95:9-17. PMID: PMC6354252.
42. ***Samples H**, Bandara SN, Olfson M, Saloner B. Tobacco Screening and Counseling in the U.S.: Smokers With Mental Health and Substance Use Problems. *Am J Prev Med*. 2018;55(4):524-532. PMID: PMC6363105.
*Selected for Continuing Medical Education (CME) program
43. Bandara SN, **Samples H**, Crum RM, Saloner B. Is screening and intervention associated with treatment receipt among individuals with alcohol use disorder? Evidence from a national survey. *J Subst Abuse Treat*. 2018;92:85-90. PMID: PMC6423981.
44. *Huskamp HA, **Samples H**, Hadland SE, McGinty E, Gibson T, Goldman H, Busch S, Stuart E, Barry C. Mental health spending and intensity of service use among individuals with diagnoses of eating disorders following federal parity. *Psychiatr Serv*. 2018;69(2):217-223. PMID: PMC5794569.
*Selected as Editor's Choice for Mental Health and Substance Use Disorder Parity Collection (Feb 2024)
45. McGinty EE, **Samples H**, Bandara SN, Saloner B, Bachhuber MA, Barry CL. The Emerging Public Discourse on State Legalization of Marijuana for Recreational Use in the US: Analysis of News Media Coverage, 2010-2014. *Prev Med*. 2016;90:114-120.
46. ***Samples H**, Mojtabai R. Antidepressant Self-Discontinuation: Results From the Collaborative Psychiatric Epidemiology Surveys. *Psychiatr Serv*. 2015;66(5):455-462.
*Published with commentary: Olfson M. Bringing antidepressant self-discontinuation into view. *Psychiatr Serv*. 2015;66(5):449.
47. Broshek DK, **Samples H**, Beard J, Goodkin H. Current Practices of the Child Neurologist in Managing Sports Concussion. *J Child Neurol*. 2014;29(1):17-22.
48. **Samples H**, Mojtabai R. Antidepressant Use in the European Union: Perceived Indications and Patterns. *Psychiatr Serv*. 2013;64(3):208.
49. Bailey CM, **Samples H**, Broshek DK, Freeman JR, Barth JT. The relationship between psychological distress and baseline sports-related concussion testing. *Clin J Sport Med*. 2010;20(4):272-277.

EDITORIALS and COMMENTARIES

1. **Samples H.** Commentary on Lo-Ciganic et al.: The importance of evidence-based clinical and policy approaches to reduce opioid harms. *Addiction*. 2022;117(7):1998-1999. PMCID: PMC9203928.

BOOK CHAPTERS

1. Hasin DS, **Samples H.** Marijuana Use in the U.S.: Trends, Consequences, Changing Laws. In: Boulton ML, Wallace R (Eds.), *Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16th Edition*. New York: McGraw-Hill; 2022.

SCIENTIFIC PRESENTATIONS

*Asterisks denote trainees unless otherwise specified

1. Crystal S, Treitler P, Xie F, Stone E, **Samples H**, Miles J. Access to Buprenorphine and the Disparate Role of Payers Across States and Time: Perspectives from All-Payer Data. Oct 2024. Poster presentation, Addiction Health Services Research Conference: San Francisco, CA.
2. Treitler P, Hermida R, Miles J, **Samples H**, Stone E, Crystal S. State variation in medication receipt following new opioid use disorder diagnosis among Medicaid enrollees in 42 states, 2016-2019. Oct 2024. Poster presentation, Addiction Health Services Research Conference: San Francisco, CA.
3. Crystal S, Treitler P, **Samples H**, Hermida R, Miles J. Medication for opioid use disorder receipt and opioid overdose among U.S. Medicaid enrollees newly diagnosed with opioid use disorder from 2016-2019. Oct 2024. Oral presentation, Addiction Health Services Research Conference: San Francisco, CA.
4. Miles J, Treitler P, Hermida R, *Nowels M, Davidson K, **Samples H**, Gupta S, Duncan A, Baaklini V, Simon K, Crystal S. National trends in racial and ethnic disparities in medication for opioid use disorder treatment among Medicaid beneficiaries with opioid use disorder, 2017-2019. Oct 2024. Oral presentation, Addiction Health Services Research Conference: San Francisco, CA.
5. Stone E, *Bonsignore S, **Samples H**. Experience of Healthcare Services Among Disabled U.S. Adults. Podium presentation, Interdisciplinary Association for Population Health Science Annual Meeting, Sep 2024: St. Louis, MO.
6. Bushnell GA, Lloyd K, Olfson M, Shiao S, Gerhard T, Keyes K, Cerda M, Hasin D, **Samples H**. Nationwide prescribing of controlled substances to adolescents and young adults in Medicaid, 2001-2019. Aug 2024. Poster presentation, International Conference on Pharmacoepidemiology: Berlin, Germany.
7. *Cruz N, **Samples H**, Crystal S, Xie F, Olfson M, Bushnell G. National Trends in Benzodiazepine Prescribing by Provider Type in Children and Adults, 2013-2022. Aug 2024. Oral presentation, International Conference on Pharmacoepidemiology: Berlin, Germany.
*Scholarship Award
8. *Cruz N, Bushnell G, Keyes K, Olfson M, **Samples H**. Temporal Trends in Emergency Department Visits for Suicidal Thoughts and Behaviors among Commercially Insured Youth Before and During the COVID-19 Pandemic, 2016-2022. Jul 2024. Oral presentation, Annual Research Meeting of Academy Health: Baltimore, MD.
*Alice S. Hersh Student Scholarship Award

9. Lloyd K, Rege S, Crystal S, Olfson M, Horton D, **Samples H**. Validation of Comprehensive Managed Care Encounter Data for Children in National Medicaid Research Files. Jun 2024. Poster presentation, Annual Research Meeting of Academy Health: Baltimore, MD.
10. Miles J, Treitler P, Hermida R, *Nowels M, **Samples H**, Gupta S, Duncan S, Baaklini V, Simon K, Crystal S. National and State-Level Racial and Ethnic Disparities in Medication Treatment Among Medicaid Beneficiaries with Opioid Use Disorder, 2017-2019. Jul 2024. Poster presentation, Annual Research Meeting of Academy Health: Baltimore, MD.
11. Treitler P, Hermida R, **Samples H**, Crystal S. Medication receipt and opioid overdose among U.S. Medicaid enrollees newly diagnosed with opioid use disorder from 2016-2019. Jun 2024. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Montreal, Canada.
12. Shiau S, Drago F, Getz K, Bushnell G, **Samples H**, Bender A, Bennett L, Halkitis PN, Gerhard T, Roy JA, Martins SS, Yin MT, Crystal S. Prescription opioid use and disorder among older adults with HIV in the US from 2008-2019. Mar 2024. Podium and poster presentations, Conference on Retroviruses and Opportunistic Infections: Denver, CO.
13. **Samples H**, *Nowels M, Williams AR, Olfson M, Crystal S. Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. Oct 2023. Podium presentation, Addiction Health Services Research Conference: New York, NY.
14. **Samples H**, Ryali R, Martins SS, Cerda M, Hasin D, Crystal S, Olfson M. Completeness and Quality of Managed Care Data for Research Using National Medicaid Files: A Validation Study. Jun 2023. Podium presentation, Annual Research Meeting of Academy Health: Seattle, WA.
15. *Nowels M, Kozlov E, **Samples H**, Olfson M, Gusmano M, Crystal S, Duberstein P. Palliative Care Use Reduces Suicide Risk Among Medicare Enrollees with Incident Metastatic Cancer Diagnoses. Jun 2023. Podium presentation, Annual Research Meeting of Academy Health: Seattle, WA.
16. Miles J, Treitler P, *Nowels M, Xie F, **Samples H**, Crystal S. Trends in Buprenorphine Prescription Fills 2013-2022: Variations By Payer and Age before and after the COVID-19 Public Health Emergency. Jun 2023. Poster presentation, Annual Research Meeting of Academy Health: Seattle, WA.
17. **Samples H**, Williams AR, Olfson M, Crystal S. Prescription opioid tapering patterns prior to discontinuation of long-term, high-dosage treatment episodes among adult Medicaid enrollees. Jun 2023. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.
18. Fink DS, **Samples H**, Saxon A, Malte C, Wall MM, Hasin DS. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019. Jun 2023. Poster Presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.
19. Fink DS, **Samples H**, Saxon A, Malte C, Wall MM, Hasin DS. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019. Jun 2023. Podium presentation, Annual Meeting of the Society for Epidemiologic Research: Portland, OR.
20. *Nowels M, Duberstein PR, Crystal S, Treitler P, Olfson M, **Samples H**. Predictors of death by suicide among Medicare disability enrollees surviving medically-treated opioid overdoses. Apr 2023. Podium presentation, Annual Suicide Research Symposium.
21. *Cruz NA, Kleiman EM, **Samples H**. Exploring the Relationship between Eating Disorders, Suicidality, Adversity, and COVID-19 among U.S. College Students. Apr 2023. Poster presentation, Annual Suicide Research Symposium.

22. *Cruz NA, **Samples H**. Risk Factors for Suicide Attempts in a Nationally Representative Sample of Adolescents Aged 12-17. Mar 2023. Poster presentation, Annual Meeting of the American Psychopathological Association: New York, NY.
23. *Cruz NA, **Samples H**. Characteristics Associated with Suicidal Ideation and Suicide Attempts in a Nationally Representative Sample of Adolescents Aged 12-17. Mar 2023. Poster presentation, Annual Meeting of the American Psychopathological Association: New York, NY.
*Scholarship award
24. Treitler P, *Nowels M, **Samples H**, Crystal S. Evaluating the relationship of state Medicaid initiatives with patient- and provider-level changes in buprenorphine treatment for opioid use disorder. Jan 2023. Poster presentation, International Conference on Health Policy Statistics: Scottsdale, AZ.
25. Hamilton L, Wheeler-Martin K, Davis CS, Martins SS, **Samples H**, Cerdá M. Expert Consensus on the Most Beneficial and Harmful Opioid Laws: A Policy Delphi Process. Jun 2022. Poster presentation, Annual Meeting of the Society for Epidemiologic Research: Chicago, IL.
26. *Memon A, **Samples H**. Assessing the Effects of Insurance from the ACA on Primary Health Outcomes in the United States. May 2022. Poster presentation, Lloyd C. Gardner Annual Research & Policy Conference: Piscataway, NJ.
27. **Samples H**, Williams AR, Crystal S, Olfson M. Characteristics of new long-term prescription opioid treatment episodes among Medicaid enrollees with chronic non-cancer pain. Oct 2021. Poster presentation, Addiction Health Services Research Conference.
28. *Nowels M, **Samples H**, Treitler P, Olfson M, Crystal S. Overdose Mortality Following a Medically Treated Opioid Overdose in Medicare Disability Enrollees, 2008-2016. Oct 2021. Poster presentation, Addiction Health Services Research Conference.
*Trainee
29. Williams AR, Mauro C, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Non-Prescribed Buprenorphine and Clinical Outcomes for Opioid Use Disorder. Oct 2021. Poster presentation, Addiction Health Services Research Conference.
30. Nguyen T, Gupta S, Ziedan E, Miles J, **Samples H**, Crystal S, Simon K. Racial/ethnic disparities in access to MOUD during the Covid-19 Pandemic. Oct 2021. Poster presentation, Addiction Health Services Research Conference.
31. Miles J, Treitler P, **Samples H**, Hermida R, Nyaku A, Simon K, Gupta S, Ziedan E, Crystal S. Racial/ethnic disparities in buprenorphine initiation among Medicare disability beneficiaries Oct 2021. Poster presentation, Addiction Health Services Research Conference.
32. Mauro P, Gutkind S, **Samples H**. Epidemiology of Medication for Opioid Use Disorder Utilization in the United States in 2019. Jun 2021. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.
33. Brown Q, **Samples H**, Montgomery L, Hasin D, Campbell C, Crystal S. Cannabis Use and Perceived Risk among Pregnant Women in the US by Trimester. Jun 2021. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.
34. Martins SS, Bruzelius E, Stingone JA, Wheeler-Martin K, Akbarnejad H, Mauro CM, Marziali M, **Samples H**, Crystal S, Davis CS, Rudolph KE, Keyes KM, Hasin DS, Cerdá M. Dec 2020. Prescription opioid laws and opioid-related harm: Identifying salient opioid policy features with machine learning. Poster presentation, Annual Meeting of the Society for Epidemiologic Research.
35. ***Samples H**, Williams AR, Olfson M, Crystal S. Patterns of Psychosocial and Behavioral Therapy Received in Conjunction with Buprenorphine Treatment. Oct 2020. Podium (award) and poster presentations, Addiction Health Services Research Conference.
*Early Career Investigator Award

36. Crystal S, Nowels M, Hermida R, Williams AR, **Samples H**, Olfson M. Medically Treated Opioid Overdoses in NJ Medicaid Beneficiaries 2014-2017: Rapid Growth with Complex Comorbidity. Jun 2020. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.
37. **Samples H**, Williams AR, Crystal S, Olfson M. Reduced Adverse Health Care Outcomes with Continuous Buprenorphine Treatment Beyond 6 to 9 Months. Oct 2019. Podium presentation, Addiction Health Services Research Conference: Park City, UT.
38. Williams AR, **Samples H**, Crystal S, Olfson M. Long-term buprenorphine treatment for OUD and adverse events following discontinuation among Medicaid beneficiaries. Oct 2019. Podium presentation, Addiction Health Services Research Conference: Park City, UT.
39. Crystal S, Nowels M, Hermida R, Williams AR, **Samples H**, Olfson M. Medically Treated Opioid Overdoses among Medicaid Beneficiaries: Changing Profiles and Evolving Clinical Challenges. Oct 2019. Poster presentation, Addiction Health Services Research Conference: Park City, UT.
40. **Samples H**, Williams AR, Crystal S, Olfson M. Reduced adverse health care utilization outcomes among Medicaid enrollees with buprenorphine treatment continuity vs. discontinuation after 6-9 months. Jun 2019. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Antonio, TX.
41. **Samples H**, Williams AR, Olfson M, Crystal S. Risk Factors for Premature Discontinuation of Buprenorphine Treatment for Opioid Use Disorder among Medicaid Enrollees. Jun 2018. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Diego, CA.
42. *Muehleisen N, *Rehman S, **Samples H**, Mauro P. Opioid Treatment Program Moratoriums and Medication Access. Jul 2018. Poster presentation, BEST Diversity Research Poster Symposium: New York, NY.
43. Mauro PM, **Samples H**, Klein KS, Martins SS. Are discussions about substance use in health care settings associated with substance use disorder treatment use and perception of treatment need? Jun 2018. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Diego, CA.
44. **Samples H**, Williams AR, Olfson M, Crystal S. Predictors of Buprenorphine Treatment Discontinuation in a Medicaid Population with Opioid Use Disorder. May 2018. Poster presentation, The Opioid Tsunami: Prevention, Partnerships in Opioid Management, and Current Issues; Annual Isabel Maitland Stewart Conference on Research in Nursing: New York, NY.
45. **Samples H**, Williams AR, Olfson M, Crystal S. Duration of Medication-Assisted Treatment for Opioid Use Disorders Among Adults with Medicaid Insurance. Mar 2018. Podium presentation, NIDA/NIMH T32 meeting at the Annual Meeting of the American Psychopathological Association, New York, NY.
46. Broshek DK, **Samples HL**, Beard JB, Goodkin HP. Current Practices of the Pediatric Neurologist in the Management of Sports Concussion. Oct 2011. Poster presentation, Annual Meeting of the Child Neurology Society: Savannah, GA.
47. Sanders JF, **Samples HL**, Bailey CM, Cuttita K, Broshek DK, Freeman JR, Barth JT. Differences in Preseason Baseline Functioning & Cognitive Efficiency of Athletes with ADHD/LD and Controls. May 2010. Poster presentation, University of Virginia Research and Scholars Day: Charlottesville, VA.
48. Sanders JF, **Samples HL**, Bailey CM, Broshek, DK, Freeman JR, Barth JT. The Effects of Attention Deficit Hyperactivity Disorder and Learning Disability on Baseline Neurocognitive Evaluation in Collegiate Athletes. May 2010. Poster presentation, Annual Meeting of the

American Academy of Clinical Neuropsychology: Chicago, IL.

49. Bailey CM, **Samples HL**, Broshek DK, Barth JT, Freeman JR. The Influence of Psychological Symptoms on Baseline Concussion Testing. Nov 2009. Poster presentation, Annual Conference of the National Academy of Neuropsychology: New Orleans, LA.

INVITED PRESENTATIONS and EXTERNAL SEMINARS

1. Medication treatment and outcomes among opioid overdose survivors with public health insurance. Feb 2025. Opioids Core, Veterans Aging Cohort Study (VACS) Consortium, Yale School of Medicine: New Haven, CT.
2. Opioid use disorder treatment patterns and outcomes. Feb 2025. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
3. Completeness and quality of comprehensive managed care encounter data for children in national Medicaid research files. Sep 2024. Medicaid Data Learning Network (MDLN), Academy Health: Washington, DC.
4. *Miles J, Treitler P, Hermida R, Samples H, Gupta S, Duncan A, Baaklini V, Simon K, Crystal S. Racial and ethnic disparities in buprenorphine receipt among Medicare beneficiaries, 2015-19. Oct 2023. Tackling Structural Racism in Health, Health Affairs Briefing: [Virtual](#).
*Presenter
5. National trends in suicidal ideation and attempts. May 2023. Suicide Risk Reduction Project, The Pew Charitable Trusts: Washington, DC.
6. Reducing disparities in suicide-related treatment and outcomes in an evolving risk environment. Feb 2023. Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV (CHERISH), Weill Cornell Medicine: New York, NY.
7. Identifying targets to address disparities in suicide prevention and mortality in an evolving risk environment. Dec 2022. Suicide Prevention and Research Center (SPARC), Rutgers University: New Brunswick, NJ.
8. Completeness and quality of managed care data in national Medicaid claims: A validation study. Nov 2022. Medicaid Data Learning Network (MDLN), Academy Health: Washington, DC.
9. Research to inform evidence-based approaches to address the opioid epidemic. Sep 2022. Rutgers Addiction Research Center (RARC) Retreat: Piscataway, NJ.
10. Opioid use disorder treatment and mortality risk after non-fatal opioid overdose. Mar 2022. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
11. Trajectories of long-term prescription opioid use and adverse opioid-related outcomes. Oct 2021. Division on Comparative Effectiveness and Outcomes Research Seminar, Weill Cornell Medicine Population Health Sciences: New York, NY.
12. Prescription opioid treatment and risk of adverse opioid-related outcomes among individuals with chronic pain. Jul 2021. Special Populations Core Webinar Series, NJ Alliance for Clinical and Translational Science (NJ ACTS): New Brunswick, NJ.
13. Patterns of opioid-related prescription drug use and the association with clinical outcomes. Jun 2021. Center for Pharmacoepidemiology and Treatment Science (PETS) Seminar, Rutgers Institute for Health, Health Care Policy and Aging Research: New Brunswick, NJ.
14. Buprenorphine treatment duration: All-cause and opioid-specific clinical benefits of continuous care. May 2020. Division on Substance Use Disorders Training Program, Department of Psychiatry, Columbia University Irving Medical Center: New York, NY.
15. A translational approach to understanding the opioid epidemic and identifying targets for

- intervention. May 2019. Population Health Research Seminar, New York University School of Medicine: New York, NY.
16. Opioid addiction treatment duration and outcomes in Medicaid populations. Dec 2018. Consortium on Applying Evidence to Improve Care and Outcomes for Individuals with Co-occurring Severe Mental Illness and Substance Use Disorders, Institute for Health, Health Care Policy and Aging Research, Rutgers University: New Brunswick, NJ.
 17. Opioid addiction treatment continuity and health care utilization in Medicaid. Nov 2018. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
 18. Determinants of retention in buprenorphine treatment among Medicaid patients with opioid use disorders. Feb 2018. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
 19. An investigation of capacity to consent to research. Aug 2014. Presidential Commission for the Study of Bioethical Issues, Department of Health and Human Services: Washington, D.C.

TEACHING

Course Director/Primary Instructor

Department of Health Behavior, Society and Policy, Rutgers School of Public Health

- Mental Health Systems and Policy (HBSP0680; 3 credits) Fall 2024
- Mental Health Services and Systems (HBSP0680; 3 credits) Fall 2023
- Health Systems & Policy (PHCO0501; 3 credits) Spring 2023

Guest Lecturer

- Intermediate Pharmacoepidemiology (EPID0676) Fall 2024
Department of Biostatistics and Epidemiology, Rutgers School of Public Health
- Introduction to Mental Health Services (PH.330.664) Fall 2024
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health
- Understanding Suicide (HBSP0682) Fall 2024
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
- Intermediate Pharmacoepidemiology (EPID0676) Fall 2023
Department of Biostatistics and Epidemiology, Rutgers School of Public Health
- Intermediate Pharmacoepidemiology (EPID0676) Fall 2022
Department of Biostatistics and Epidemiology, Rutgers School of Public Health
- Analysis of Real-World Pharmacoepidemiological Data (EPID0678) Fall 2022
Department of Biostatistics and Epidemiology, Rutgers School of Public Health
- General Psychiatry Residency Program Didactics Fall 2022
Department of Psychiatry, Robert Wood Johnson Medical School
- Doctoral Colloquium (RESH0701) Fall 2022
Rutgers School of Public Health

Teaching Assistant

Johns Hopkins Bloomberg School of Public Health

- The Research and Proposal Writing Process 2015 – 2016
- Research Ethics and Integrity: U.S. and International Issues 2015 – 2016
- Introduction to Bioethics in Public Health Practice and Research 2013 – 2016
- Assessing Health Status and Patient Reported Outcomes 2015

- Urban Policy 2015
- Ethical Issues in Health Policy: Public Health and Health Care 2014

PROFESSIONAL SOCIETIES

- International Society for Pharmacoepidemiology 2022 – present
- College on Problems of Drug Dependence 2018 – present
- American Psychopathological Association 2018 – present
- Society for Epidemiologic Research 2017 – present
- American Statistical Association 2015 – present
- Academy Health 2014 – present
- American Society of Addiction Medicine 2019
- New York Academy of Sciences 2017 – 2018

ACADEMIC SERVICE

Grant Review

- NIH/NIDA Special Emphasis Panel (ZDA1 MXY-T (M1) 1) 2025
Loan Repayment Program
- NIH/NIDA Special Emphasis Panel (10 ZDA1 SAI-C (O1) R) 2024
The National Drug Abuse Treatment Clinical Trials Network
- NIH/NIDA Special Emphasis Panel (ZDA1 SUY-T (A1)) 2024
Loan Repayment Program
- NIH/NIDA Special Emphasis Panel (ZDA1 MXS-E (A1) R) 2023
HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants
- NIH/NIDA Center for the Clinical Trials Network (CTN) 2023
Protocol review to evaluate scientific rigor, design, methods, and safety

Ad-Hoc Peer Review

- **Journals**
 - General medicine: JAMA; JAMA Network Open; Annals of Internal Medicine; Journal of General Internal Medicine; American Journal of Preventive Medicine; Pediatrics
 - Public health: American Journal of Public Health
 - Health policy & services: Health Affairs; Medical Care
 - Psychiatry/substance use: Psychiatric Services; Addiction; Drug and Alcohol Dependence; Drug and Alcohol Dependence Reports; Journal of Substance Use and Addiction Treatment; Journal of Addiction Medicine; Substance Abuse Treatment, Prevention, and Policy; International Journal of Mental Health and Addiction; Journal of Psychiatric Research
- **Conference Abstracts**
 - Addiction Health Services Research* 2024
 - Society for Epidemiologic Research* 2022
- **Peer group Research On Mentoring Scientists (PROMISE) Study** 2022
Duke University, NIH Diversity Program Consortium

National Committees

- Site Lead, Medicaid Data Learning Network (MDLN) 2022 – present
Evidence-Informed State Health Policy Institute, Academy Health
- Addiction Health Services Research (AHSR) Planning Committee 2020 – present
Abstracts Subcommittee 2023 – 2024
Pre-conference Workshops Subcommittee 2022 – 2023
Investigator Awards Subcommittee 2020 – 2021

University Committees

- Doctoral and Postdoctoral Training Award (TL1) Review Committee 2023
New Jersey Alliance for Clinical and Translational Sciences (NJ ACTS)

Department Committees

- Faculty Search Committee 2024 – 2025
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
- Practicum Committee 2024
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
- Doctoral Admissions Committee 2023 – 2024
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
- PhD Qualifying Exam Committee 2022 – 2023
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
- Faculty Search Committee 2020 – 2022
Center for Health Services Research, Rutgers Institute for Health, Health Care Policy and Aging Research
- Population Mental Health Curriculum Development Committee 2020 – 2021
Department of Health Behavior, Society and Policy, Rutgers School of Public Health

Facilitator, Interprofessional Education

- 2020, 2024
Department of Health Behavior, Society and Policy, Rutgers School of Public Health

COMMUNITY SERVICE

Overdose Fatality Review Team

- 2024
Office of Health Services, Middlesex County, New Jersey

MENTORSHIP and TRAINING

Doctoral Dissertation Mentor and Committee Chair

Department of Health Behavior, Society and Policy, Rutgers School of Public Health

- Naomi Cruz, PhD candidate expected 2026
Awarded the Howard Leventhal Scholarship for Doctoral Research
- Allison Stitt, DrPH candidate expected 2025

Doctoral Dissertation Committee Member

- Molly Nowels, PhD 2024
Department of Health Behavior, Society and Policy, Rutgers School of Public Health
Awarded the Howard Leventhal Scholarship for Doctoral Research
- Allison Perry, PhD 2024
Division of Epidemiology, Department of Population Health, NYU Grossman School of Medicine

Master of Public Health (MPH) Practicum and Capstone Advisor

Department of Health Behavior, Society and Policy, Rutgers School of Public Health

- Amani Pascall expected 2026
- Kwarysha Howard expected 2026
- Ryan Kreutzberg expected 2026
- Hemal Patel expected 2026
- Ethan Lee (practicum) expected 2025
- Alejandra Murillo 2025
- Sofia Bonsignore 2024
- Emily Thampoe 2024
- Peter Fam 2024
- Connor Griffin 2023
- Ethan Pardun 2022

Mentor

2020 – present

Addiction Health Services Research (AHSR) Mentoring Program

Mentor, Lloyd C. Gardner Fellowship Program

2021 – 2022

School of Arts and Sciences, Rutgers University

Co-Mentor, Biostatistics Epidemiology Summer Training (BEST) Diversity Program 2018

Department of Epidemiology, Columbia University Mailman School of Public Health

OTHER PROFESSIONAL EXPERIENCE

Consultant, Suicide Risk Reduction Project

2022 – 2024

The Pew Charitable Trusts

- [Fact Sheet](#): Substance Use Disorder Increases Risk of Suicidal Thoughts and Attempts
- [Article](#): Suicide Risk Increasing and Many High-Risk People Don't Receive Mental Health Care
- [Data Visualization](#): U.S. National Trends and Disparities in Suicidal Ideation, Suicide Attempts, and Health Care Use

Consultant, Clinical Technical Support Services

2018 – 2020

American Society of Addiction Medicine

Research Fellow

2014

Presidential Commission for the Study of Bioethical Issues, U.S. Department of Health and Human Services

Research Program Coordinator

2013

Johns Hopkins Berman Institute of Bioethics

Consultant, Clinical Research Coordination

2012 – 2013

University of Virginia School of Medicine

Clinical Research Coordinator

2008 – 2012

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine

Certified Clinical Research Coordinator

2011 – 2013

Neuro-Psychometrist

2007 – 2011

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System

Certified Specialist in Psychometry

2009 – 2011